Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
2.
J Neurosci ; 25(47): 10857-62, 2005 Nov 23.
Article in English | MEDLINE | ID: mdl-16306398

ABSTRACT

Neurofibrillary tangles (NFTs), neuropil threads, and neuritic elements of senile plaques predominantly comprise hyperphosphorylated tau protein and represent pathological characteristics of Alzheimer's disease (AD). These lesions occur before the presentation of clinical symptoms and correlate with the severity of dementia. In vivo detection of these lesions would thus prove useful for preclinical diagnosis of AD and for tracking disease progression. The present study introduces three novel compounds, 4-[2-(2-benzoimidazolyl)ethenyl]-N,N-diethylbenzenamine (BF-126), 2-[(4-methylamino)phenyl]quinoline (BF-158), and 2-(4-aminophenyl)quinoline (BF-170), as candidate probes for in vivo imaging of tau pathology in the AD brain. When solutions of these compounds are injected intravenously into normal mice, these agents exhibit excellent brain uptake and rapid clearance from normal brain tissue. These compounds display relatively lower binding affinity to beta-amyloid fibrils and higher binding affinity to tau fibrils, compared with previously reported probe BF-168. In neuropathological examination using AD brain sections, BF-126, BF-158, and BF-170 clearly visualize NFTs, neuropil threads, and paired helical filament-type neuritis. Autoradiography using 11C-labeled BF-158 further demonstrated labeling of NFTs in AD brain sections. These findings suggest the potential usefulness of quinoline and benzimidazole derivatives for in vivo imaging of tau pathology in AD.


Subject(s)
Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Aniline Compounds , Benzimidazoles , Brain/metabolism , Quinolines , tau Proteins/metabolism , Aged , Amyloid/metabolism , Aniline Compounds/administration & dosage , Aniline Compounds/metabolism , Aniline Compounds/pharmacokinetics , Animals , Autoradiography , Benzimidazoles/administration & dosage , Benzimidazoles/metabolism , Benzimidazoles/pharmacokinetics , Binding, Competitive , Brain/pathology , Female , Humans , Injections, Intravenous , Male , Mice , Mice, Inbred ICR , Neurofibrillary Tangles/metabolism , Neurofibrillary Tangles/pathology , Positron-Emission Tomography , Quinolines/administration & dosage , Quinolines/metabolism , Quinolines/pharmacokinetics
3.
Ann Neurol ; 57(6): 832-42, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15929037

ABSTRACT

Amyloid beta peptide (A beta) has been implicated in Alzheimer's disease (AD) as an initiator of the pathological cascades. Several lines of compelling evidence have supported major roles of A beta-degrading enzyme neprilysin in the pathogenesis of sporadic AD. Here, we have shown a substantial reduction of cerebrospinal fluid (CSF) neprilysin activity (CSF-NEP) in patients with AD-converted mild cognitive impairment and early AD as compared with age-matched control subjects. The altered CSF-NEP likely reflects changes in neuronal neprilysin, since transfer of neprilysin from brain tissue into CSF was demonstrated by injecting neprilysin-carrying viral vector into the brains of neprilysin-deficient mice. Interestingly, CSF-NEP showed an elevation with the progression of AD. Along with a close association of CSF-NEP with CSF tau proteins, this finding suggests that presynaptically located neprilysin can be released into CSF as a consequence of synaptic disruption. The impact of neuronal damages on CSF-NEP was further demonstrated by a prominent increase of CSF-NEP in rats exhibiting kainate-induced neurodegeneration. Our results unequivocally indicate significance of CSF-NEP as a biochemical indicator to pursue a pathological process that involves decreased neprilysin activity and A beta-induced synaptic toxicity, and the support the potential benefits of neprilysin up-regulation in ameliorating neuropathology in prodromal and early AD.


Subject(s)
Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/pathology , Neprilysin/cerebrospinal fluid , Aged , Alzheimer Disease/blood , Animals , Biomarkers/blood , Biomarkers/cerebrospinal fluid , Down-Regulation , Early Diagnosis , Excitatory Amino Acid Agonists/pharmacology , Female , Genetic Vectors , Hippocampus/metabolism , Hippocampus/pathology , Humans , Kainic Acid/pharmacology , Male , Mice , Neprilysin/blood , Neprilysin/genetics , Rats
4.
J Am Geriatr Soc ; 53(5): 824-8, 2005 May.
Article in English | MEDLINE | ID: mdl-15877558

ABSTRACT

OBJECTIVES: To determine whether oral capsaicin troche supplementation with every meal upregulates the impairment of upper respiratory protective reflexes such as the swallowing reflex and the cough reflex. DESIGN: Randomized, controlled study with recruitment through nursing homes. SETTING: Sendai, Japan, from September 2002 through December 2003. PARTICIPANTS: Sixty-four participants in nursing homes with a mean age+/-standard deviation of 81.9+/-1.0 with stable physical status. INTERVENTION: Participants were randomly assigned to the program for the supplementation of capsaicin trochisci or placebo trochisci before every meal for 4 weeks. MEASUREMENTS: Assessment of individual latency time of the swallowing reflex (LTSR) and cough reflex sensitivity. RESULTS: Before the commencement of this study, there were no significant baseline differences in multiple parameters between the intervention group and control group. LTSR in participants in the intervention group was significantly shorter than in the control group (P<.05). The odds ratio (OR) of the shortening of the LTSR of more than 1 minute in the intervention group was 3.4 (95% confidence interval (CI)=1.1-10.4), compared with the control group (P=.03). In particular, daily capsaicin supplementation significantly increased the ratio of LTSR reduction at 4 weeks after the study to baseline LTSR in the high-risk group (baseline LTSR >6.0 seconds) compared with the low-risk group (baseline LTSR <3.0 seconds) and the intermediate group (3.0 seconds

Subject(s)
Capsaicin/administration & dosage , Deglutition Disorders/drug therapy , Administration, Oral , Aged , Aged, 80 and over , Deglutition/drug effects , Female , Humans , Male , Reaction Time/drug effects , Reflex/drug effects , Tablets , Up-Regulation
5.
Am J Respir Crit Care Med ; 171(11): 1246-51, 2005 Jun 01.
Article in English | MEDLINE | ID: mdl-15764730

ABSTRACT

RATIONALE: Exhaled carbon monoxide (CO) and arterial blood carboxyhemoglobin concentrations (Hb-CO) increase in inflammatory pulmonary diseases. OBJECTIVES: To study whether arterial Hb-CO is useful to monitor disease activity in patients with chronic obstructive pulmonary disease (COPD) who had stopped smoking. METHODS: We measured arterial Hb-CO, arteriovenous Hb-CO differences, and FEV1 in 58 patients with COPD and 61 ex-smoking control subjects. RESULTS: Arterial Hb-CO concentrations in patients at stable conditions were higher than those in control subjects (p < 0.0001). Furthermore, the Hb-CO concentrations in patients at the exacerbations (p < 0.0001) were higher than those at the stable conditions. Arterial Hb-CO concentrations in patients at stage III were higher than those in patients at stage II, and the Hb-CO concentrations in patients at stage IV were higher than those in patients at stage III at the stable conditions and exacerbations. Arterial Hb-CO correlated with exhaled CO in patients with COPD at stage II and stage III at the exacerbations. Arterial Hb-CO inversely correlated with the arterial blood partial oxygen pressure and FEV1. Arteriovenous Hb-CO differences in patients at the exacerbations did not differ from those in patients at stable conditions and from those in control subjects. Moreover, arterial Hb-CO correlated with serum C-reactive protein values and serum lipid peroxide concentrations. CONCLUSIONS: These findings suggest that increased arterial Hb-CO may relate to severity in patients with COPD because of lung and systemic inflammation and production of reactive oxygen species.


Subject(s)
Carboxyhemoglobin/metabolism , Pulmonary Disease, Chronic Obstructive/blood , Aged , Arteries , Breath Tests , Carbon Dioxide/analysis , Female , Humans , Male , Pulmonary Disease, Chronic Obstructive/classification , Pulmonary Disease, Chronic Obstructive/diagnosis , Respiratory Function Tests , Veins
6.
J Clin Psychiatry ; 66(2): 248-52, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15705012

ABSTRACT

OBJECTIVE: This randomized, observer-blind, controlled trial examined the efficacy and safety of the traditional Chinese herbal medicine Yi-Gan San (YGS, Yokukan-San in Japanese) in the improvement of behavioral and psychological symptoms of dementia (BPSD) and activities of daily living (ADL). METHOD: Fifty-two patients with mild-to-severe dementia (24 men and 28 women, mean +/- SD age = 80.3 +/- 9.0 years) according to DSM-IV criteria were investigated. Participants were randomly assigned to the YGS group (N = 27) or control (drug-free) group (N = 25) and treated for 4 weeks. The Neuropsychiatric Inventory (NPI) for the assessment of BPSD, the Mini-Mental State Examination (MMSE) for cognitive function, and the Barthel Index for ADL were administered at baseline and the end of the treatment. The frequency of extrapyramidal symptoms (EPS) and other adverse events was recorded. If patients showed insufficient response to treatment after 1 week, tiapride hydrochloride, a dopamine D(1) selective neuroleptic, was added to the regimen. Data were collected from January 2004 to March 2004. RESULTS: All participants in both groups completed the trial. In the control group, 11 patients required treatment with tiapride hydrochloride. Significant improvements in mean +/- SD NPI (from 37.9 +/- 16.1 to 19.5 +/- 15.6) and Barthel Index (from 56.4 +/- 34.2 to 62.9 +/- 35.2) scores were observed in the YGS group, but not in the control group. MMSE results were unchanged in both groups. EPS were not observed in either group, but dizziness and impaired postural sway were observed in 6 patients treated with tiapride hydrochloride. CONCLUSION: Yi-Gan San improves BPSD and ADL. Follow-up studies using a double-blinded, placebo-controlled design are recommended.


Subject(s)
Activities of Daily Living/psychology , Dementia/drug therapy , Drugs, Chinese Herbal/therapeutic use , Medicine, Chinese Traditional , Aged , Aged, 80 and over/psychology , Basal Ganglia Diseases/chemically induced , Behavioral Symptoms/drug therapy , Behavioral Symptoms/psychology , Dementia/diagnosis , Dementia/psychology , Dopamine Antagonists/therapeutic use , Drug Therapy, Combination , Drugs, Chinese Herbal/adverse effects , Female , Humans , Male , Phytotherapy , Psychiatric Status Rating Scales , Tiapamil Hydrochloride/therapeutic use , Treatment Outcome
7.
Neurodegener Dis ; 2(6): 299-304, 2005.
Article in English | MEDLINE | ID: mdl-16909012

ABSTRACT

BACKGROUND: Cerebrovascular disease is common in Alzheimer's disease (AD). Elevated plasma homocysteine (pHcy) levels are reported to be associated with an increased risk of poor cognition and dementia. OBJECTIVE: To determine whether high pHcy levels are associated with an increased risk of coexisting silent brain infarctions (SBIs) in AD. METHODS: Study population comprising 143 outpatients with clinical diagnosis of probable AD (73.3 +/- 7.0 years) were classified into 2 groups according to the presence or absence of SBIs on magnetic resonance imaging. RESULTS: SBIs were noted in 32.9% (47/143) of the AD patients. The pHcy levels in the AD with SBIs (14.0 +/- 4.5 micromol/l) were significant ly elevated compared with the AD without SBIs (11.7 +/- 4.7 micromol/l, p = 0.007). After adjusting for age and gender, high pHcy (>12.4 micromol/l), but not hypertension, was associated with an increased risk of developing SBIs in AD (OR = 4.61, 95% CI = 1.74-12.2, p = 0.002). However, age at onset, cognitive function, cerebrospinal tau or amyloid beta-peptide(1-42) levels were not significantly correlated with pHcy levels in AD. CONCLUSION: SBIs commonly coexist with AD, and may be a unique vascular condition in which homocysteine plays an important role. Homocysteine-lowering therapy rather than antihypertensive medication might be an appropriate strategy to prevent stroke associated with AD.


Subject(s)
Alzheimer Disease/complications , Alzheimer Disease/epidemiology , Cerebral Infarction/epidemiology , Cerebral Infarction/etiology , Homocysteine/blood , Aged , Alleles , Amyloid beta-Peptides/cerebrospinal fluid , Apolipoproteins E/genetics , Cell Death/physiology , Enzyme-Linked Immunosorbent Assay , Female , Folic Acid/blood , Genotype , Humans , Magnetic Resonance Imaging , Male , Neurons , Peptide Fragments/cerebrospinal fluid , Risk Factors , Vitamin B 12/blood , tau Proteins/cerebrospinal fluid
9.
Arch Neurol ; 61(5): 716-20, 2004 May.
Article in English | MEDLINE | ID: mdl-15148149

ABSTRACT

BACKGROUND: Mild cognitive impairment (MCI) may be a heterogeneous condition rather than a uniform disease entity. OBJECTIVE: To develop reliable tools that aid in identifying patients at risk of developing Alzheimer disease (AD) among heterogeneous populations with MCI to maximize the benefits of emerging therapies for AD. DESIGN: A 2-year prospective study. SETTING: Clinical follow-up in an outpatient memory clinic. PATIENTS: Seventy-two consecutive older patients with memory complaints. MAIN OUTCOME MEASURES: Cerebrospinal fluid tau levels, severity of periventricular and deep white matter lesions, silent brain infarction on magnetic resonance imaging, plasma homocysteine levels, apolipoprotein E genotype, and other vascular risk factors were assessed at baseline. RESULTS: Fifty-seven patients were diagnosed as having amnestic MCI. Forty-one patients with (AD-converted MCI group) or without (progressive MCI group) conversion to dementia and AD progressed over time, whereas the other 16 patients remained cognitively stable (stable MCI group). The stable MCI group was characterized by normal cerebrospinal fluid tau levels and a high grade of periventricular white matter lesions (PWMLs). The progressive MCI and AD-converted MCI groups had increased cerebrospinal fluid tau levels and low grades of PWMLs. A logistic regression model showed that age was significantly associated with developing PWMLs (P =.03; odds ratio, 1.15; 95% confidence interval, 1.0-1.3). CONCLUSIONS: Tau-related AD pathologic conditions and possibly ischemic PWMLs represent 2 major etiologies in the development of MCI, reflecting heterogeneity in the clinical progression. Because the progressive type of MCI may be a primary target of clinical trials that aim at secondary prevention of dementia, these patients should be identified by appropriate biomarkers and neuroimaging techniques.


Subject(s)
Alzheimer Disease/diagnosis , Brain/pathology , Cognition Disorders/etiology , Cognition Disorders/pathology , tau Proteins/cerebrospinal fluid , Aged , Alzheimer Disease/physiopathology , Apolipoproteins E/genetics , Biomarkers , Brain/diagnostic imaging , Cognition Disorders/physiopathology , Dementia/pathology , Dementia/physiopathology , Disease Progression , Female , Follow-Up Studies , Homocysteine/blood , Humans , Magnetic Resonance Imaging , Male , Neuropsychological Tests , Prospective Studies , Radiography , Risk Factors
10.
Seishin Shinkeigaku Zasshi ; 106(3): 269-80, 2004.
Article in Japanese | MEDLINE | ID: mdl-15164576

ABSTRACT

Recently, it has become important to diagnose Alzheimer's Disease (AD) at an early stage due to the development of AD therapy. Also, there is increasing recognition of a class of elderly people with complaints of memory loss but who nevertheless do not meet the criteria for dementia. "Mild cognitive impairment" (MCI) is the term used for this disorder, and amnestic MCI is highly converted to AD. In this study we evaluated the accuracy of diagnosis of amnestic MCI by cerebrospinal fluid total-tau protein (CSF/total-tau), cerebrospinal fluid amyloid beta 1-42 protein (CSF/A beta 1-42), and cerebral blood flow in the posterior cingulate cortex using SPECT. CSF/total-tau was the most appropriate to discriminate between normal cognitive individuals and those with amnestic MCI. We also evaluated the CSF/total-tau and MRI images between patients with stable MCI and those with progressive MCI, including those who converted to AD in the following two years. The stable type was characterized by normal CSF/total-tau levels and relatively high grade periventricular white matter lesions (PWML). Conversely, the progressive type was characterized by high CSF-tau levels and relatively low grade PWML. We speculate that stable MCI is due to ischemic change with in the white matter lesion, while progressive MCI may represent a previous stage of AD.


Subject(s)
Alzheimer Disease/diagnosis , Cognition , Alzheimer Disease/pathology , Alzheimer Disease/psychology , Amyloid beta-Peptides/cerebrospinal fluid , Biomarkers/cerebrospinal fluid , Brain/pathology , Cerebrovascular Circulation , Evidence-Based Medicine , Humans , Magnetic Resonance Imaging , Membrane Proteins/genetics , Mutation , Peptide Fragments/cerebrospinal fluid , Presenilin-1 , Sensitivity and Specificity , Severity of Illness Index , Tomography, Emission-Computed, Single-Photon , tau Proteins/cerebrospinal fluid
SELECTION OF CITATIONS
SEARCH DETAIL
...